Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

There are no comments yet.

Please log in to write the first comment.